South Carolina State Ports Authority
The Port Authority of New York & New Jersey
Virginia Port Authority.

Synopsis: The proposed Agreement would permit the parties to meet, discuss, and exchange information regarding a broad range of port activities and issues of concern to the marine terminal industry. The Agreement does not authorize its members to take any collective action. Any agreement the parties might desire to implement would be filed with the Commission in accordance with the provisions of the Shipping Act of 1984, if required. The Agreement will be effective for an initial term of five years.

Agreement No.: 224–201052.

Title: Port of Oakland and Marine Terminals Corporation License and Concession Agreement.

Parties:

Port of Oakland
Marine Terminals Corporation.

Synopsis: Under the proposed agreement, the port grants Marine Terminals Corporation a license, concession and privilege, subject to the terms and conditions set forth in the agreement, to use about 25 acres, plus adjacent vessel berthing area in the Oakland Outer Harbor Area, currently leased by the port from the United States Army for an initial period expiring July 31, 1998, with options for subsequent one-year extensions.

By Order of the Federal Maritime Commission.

Dated: May 7, 1998.

Joseph C. Polking,

Secretary.

[FR Doc. 98–12584 Filed 5–11–98; 8:45 am]

BILLING CODE 6730–01–M

FEDERAL MARITIME COMMISSION

Ocean Freight Forwarder License Applicants

Notice is hereby given that the following applicants have filed with the Federal Maritime Commission applications for licenses as ocean freight forwarders pursuant to section 19 of the Shipping Act of 1984 (46 U.S.C. app. 1718 and 46 CFR 510).

Persons knowing of any reason why any of the following applicants should not receive a license are requested to contact the Office of Freight Forwarders, Federal Maritime Commission, Washington, DC 20573.

FirstAir, Inc. d/b/a SeaMasters, 980 Lone Oak Road, Suite 160, Eagan, MN 55121, Officers: Richard D. McCrady, Jr., President, Kim L. McCrady, Vice President

Logical Logistics International Ltd., 5188 Roswell Road, Atlanta, GA 30342, Officer: Alan M. Sheps, President

Provex, Inc., 6581 N.W. 82nd Avenue, Miami, FL 33166, Officer: Jose Arteaga, President

Paramount Transportation System, Inc., 100 N. Rancho Santa Fe Road, Suite #125, San Marcos, CA 92069, Officers: Mike Keller, President, Grace Bishar, Secretary/Treasurer

Ocean Transportation Services, LLC, Two Union Square, 601 Union Street, Suite 5568, Seattle, WA 98101–2327, Officers: Neal E. Gordon, President, Ernest Sarkissian, Vice President

A.C.T.S. American Christian Transportation Service, 136 Church Street, Rockaway, NJ 07866, Donald G. Andersen, Sole Proprietor

Dated: May 7, 1998.

Joseph C. Polking,

Secretary.

[FR Doc. 98–12583 Filed 5–11–98; 8:45 am]

BILLING CODE 6730–01–M

FEDERAL RESERVE SYSTEM

Formations of, Acquisitions by, and Mergers of Bank Holding Companies

The companies listed in this notice have applied to the Board for approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 *et seq.*) (BHC Act), Regulation Y (12 CFR Part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below.

The applications listed below, as well as other related filings required by the Board, are available for immediate inspection at the Federal Reserve Bank indicated. The application also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act. Unless otherwise noted, nonbanking activities will be conducted throughout the United States.

Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than June 5, 1998.

A. Federal Reserve Bank of St. Louis (Randall C. Sumner, Vice President) 411 Locust Street, St. Louis, Missouri 63102-2034:

1. Union Planters Corporation, and its second tier subsidiary, Union Planters Holding Corporation, both of Memphis, Tennessee; to acquire 100 percent of the voting shares and to merge with its wholly owned bank holding company subsidiary, Alvin Bancshares, Inc., and its wholly owned subsidiary, Alvin Bancshares, Delaware, Inc., and thereby indirectly acquire Alvin State Bank, all of Alvin, Texas.

B. Federal Reserve Bank of Minneapolis (Karen L. Grandstrand, Vice President) 90 Hennepin Avenue, P.O. Box 291, Minneapolis, Minnesota 55480-0291:

1. Merchants Holding Company, Winona, Minnesota; to acquire 32.1 percent of the voting shares of BRAD, Inc., Black River Falls, Wisconsin, and thereby indirectly acquire Black River Country Bank, Black River Falls, Wisconsin.

C. Federal Reserve Bank of Dallas (W. Arthur Tribble, President) 2200 North Pearl Street, Dallas, Texas 75201-2272:

1. WTSB Bancorp, Inc., Snyder, Texas; to become a bank holding company by acquiring 100 percent of the voting shares of WTSB Delaware Bancorp, Inc., Dover, Delaware, and thereby indirectly acquire West Texas State Bank, Snyder, Texas.

2. WTSB Delaware Bancorp, Inc., Dover, Delaware; to become a bank holding company by acquiring 100 percent of the voting shares of West Texas State Bank, Snyder, Texas.

Board of Governors of the Federal Reserve System, May 6, 1998.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 98–12454 Filed 5–11–98; 8:45 am]

BILLING CODE 6210–01–F

FEDERAL RESERVE SYSTEM

Sunshine Act Meeting

TIME AND DATE: 12:00 noon, Monday, May 18, 1998.

PLACE: Marriner S. Eccles Federal Reserve Board Building, 20th and C Streets, N.W., Washington, D.C. 20551.

STATUS: Closed.

MATTERS TO BE CONSIDERED:

1. Personnel actions (appointments, promotions, assignments, reassignments, and salary actions) involving individual Federal Reserve System employees.

2. Any matters carried forward from a previously announced meeting.

CONTACT PERSON FOR MORE INFORMATION: Joseph R. Coyne, Assistant to the Board; 202–452–3204.

SUPPLEMENTARY INFORMATION: You may call 202–452–3206 beginning at approximately 5 p.m. two business days before the meeting for a recorded announcement of bank and bank holding company applications scheduled for the meeting; or you may contact the Board's Web site at http://www.bog.frb.fed.us for an electronic announcement that not only lists applications, but also indicates procedural and other information about the meeting.

Dated: May 8, 1998.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 98–12656 Filed 5–8–98; 12:29 pm]

BILLING CODE 6210–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Pfizer, Inc.; Withdrawal of Approval of NADA's

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval of four new animal drug applications (NADA's) held by Pfizer, Inc. The NADA's provide for use of oxytetracycline hydrochloride. The sponsor requested the withdrawal of approval of the NADA's because the animal drug products are no longer manufactured or marketed.

EFFECTIVE DATE: May 12, 1998.

FOR FURTHER INFORMATION CONTACT: Dianne T. McRae, Center for Veterinary Medicine (HFV–102), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–827–0212.

SUPPLEMENTARY INFORMATION: Pfizer, Inc., 235 East 42d St., New York, NY 10017 is the sponsor of NADA 8–696 TM–5 Antibiotic Feed Supplement (oxytetracycline), NADA 10–661 Terramycin Egg Formula (oxytetracycline hydrochloride), NADA 11–034 Liquimast Solution for Mastitis (oxytetracycline hydrochloride), and NADA 13–470 TM–10 Premix (oxytetracycline). The animal drug products were subject to review under the National Academy of Sciences/National Research Council, Drug Efficacy Study Implementation Program, and are currently subject to requirements for finalization under that program. Pfizer, Inc., the current sponsor, requested withdrawal of approval of the NADA's because the animal drug products are no longer manufactured or marketed.

Therefore, under authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10) and redelegated to the Center for Veterinary Medicine (21 CFR 5.48), and in accordance with § 514.115 *Withdrawal of approval of applications* (21 CFR 514.115), notice is given that approvals of NADA's 8–696, 10–661, 11–034, 13–470, and all supplements and amendments thereto are hereby withdrawn, effective May 22, 1998.

These products had not been the subject of a regulation published under section 512 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360b). Therefore, an amendment to the animal drug regulations to reflect the withdrawal of approvals is not required.

Dated: April 24, 1998.

Stephen F. Sundlof,

Director, Center for Veterinary Medicine.

[FR Doc. 98–12612 Filed 5–11–98; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 98N–0285]

Sanofi Pharmaceuticals, Inc., et al.; Withdrawal of Approval of 21 New Drug Applications and 62 Abbreviated New Drug Applications

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval of 21 new drug applications (NDA's) and 62 abbreviated new drug applications (ANDA's). The holders of the applications notified the agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.

EFFECTIVE DATE: June 11, 1998.

FOR FURTHER INFORMATION CONTACT: Olivia A. Pritzlaff, Center for Drug Evaluation and Research (HFD–7), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–594–2041.

SUPPLEMENTARY INFORMATION: The holders of the applications listed in the table in this document have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications. The applicants have also, by their request, waived their opportunity for a hearing.

Application No.	Drug	Applicant
NDA 4–496	Pipanol Powder and Tablets (trihyphenidyl)	Sanofi Pharmaceuticals, Inc., 90 Park Ave., New York, NY 10016.
NDA 6–328	Isuprel (isoproterenol hydrochloride) Sublingual Tablets, 10 milligrams (mg) and 15 mg	Do.
NDA 7–514	Insulin, NPH Iletin	Eli Lilly and Co., Lilly Corporate Center, Indianapolis, IN 46285.
NDA 8–256	Insulin	Do.
NDA 8–717	Acetaminophen Tablets USP (acetaminophen tablets)	Roxane Laboratories, Inc., P.O. Box 16532, Columbus, OH 43216–6532.
NDA 8–847	Sucostrin (succinylcholine chloride injection)	Apothecon, Inc., P.O. Box 4500, Princeton, NJ 08543–4500.
NDA 8–983	Arfonad (trimethaphan camsylate) Ampules	Hoffmann-La Roche, Inc., 40 Kingsland St., Nutley, NJ 07110–1199.
NDA 9–088	Neothylline (dyphylline) injection	TEVA Pharmaceuticals USA (formerly Lemmon Co.), 650 Cathill Rd., Sellersvile, PA 18960.
NDA 9–300	Insulin, Lente Iletin I	Eli Lilly and Co.
NDA 9–410	Lotusate Tablets and and Capsules (talbutal)	Sanofi Pharmaceuticals, Inc.
NDA 9–479	Jayne's Liquid Vermifuge (piperazine hexahydrate)	Do.